keyword
MENU ▼
Read by QxMD icon Read
search

Lanreotide

keyword
https://www.readbyqxmd.com/read/28091879/new-medical-therapies-on-the-horizon-oral-octreotide
#1
REVIEW
Nienke R Biermasz
Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. The present review summarized the preclinical work and the recently reported phase I and III study on oral octreotide capsules in patients with acromegaly...
January 16, 2017: Pituitary
https://www.readbyqxmd.com/read/28008238/communication-practices-and-awareness-of-resources-for-acromegaly-patients-among-endocrinologists
#2
Susan Polanco-Briceno, Daniel Glass, Cindy Plunkett
PURPOSE: This study was designed to assess the awareness and utilization of resources to improve patients' treatment experiences among endocrinologists who currently treat patients with acromegaly. METHODS: A total of 4,280 US endocrinologists were randomly selected from the CMS National Plan and Provider Enumeration System and were invited by mail to participate in a 20-minute online survey. In order to qualify, respondents had to be the primary physician making treatment decisions for at least one patient for their acromegaly...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27995519/hepatic-cyst-infection-during-use-of-the-somatostatin-analog-lanreotide-in-autosomal-dominant-polycystic-kidney-disease-an-interim-analysis-of-the-randomized-open-label-multicenter-dipak-1-study
#3
Marten A Lantinga, Hedwig M A D'Agnolo, Niek F Casteleijn, Johan W de Fijter, Esther Meijer, Annemarie L Messchendorp, Dorien J M Peters, Mahdi Salih, Edwin M Spithoven, Darius Soonawala, Folkert W Visser, Jack F M Wetzels, Robert Zietse, Joost P H Drenth, Ron T Gansevoort
INTRODUCTION AND AIMS: The DIPAK-1 Study investigates the reno- and hepatoprotective efficacy of the somatostatin analog lanreotide compared with standard care in patients with later stage autosomal dominant polycystic kidney disease (ADPKD). During this trial, we witnessed several episodes of hepatic cyst infection, all during lanreotide treatment. We describe these events and provide a review of the literature. METHODS: The DIPAK-1 Study is an ongoing investigator-driven, randomized, controlled, open-label multicenter trial...
December 19, 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27972489/dose-extension-and-costs-of-lanreotide-autogel-120-mg-used-in-routine-neuroendocrine-tumors-care-in-poland-2-years-data-from-lanro-net-study
#4
E Orlewska, T Bednarczuk, G Kaminski, T Budlewski, B Kos-Kudla
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972405/evaluation-of-injectable-lanreotide-acetate-in-the-treatment-of-liver-carcinoma
#5
T R Nunes, D C Viana, M R Galdino-Pitta, P S Oliveira, M S Landim, P R Cardoso, M J Rego, F Zanghelini, M D Oliveira, C A Andrade, M G Pitta
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972167/budget-impact-analysis-of-lanreotide-autogel-120-mg-in-the-treatment-of-acromegaly-in-poland
#6
E Orlewska, B Kos-Kudla, J Sowinski, K Sworczak, W Zgliczynski
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27956089/outcome-analysis-of-first-line-somatostatin-analog-treatment-in-metastatic-pulmonary-neuroendocrine-tumors-and-prognostic-significance-of-18-fdg-pet-ct
#7
Alberto Bongiovanni, Federica Recine, Nada Riva, Flavia Foca, Chiara Liverani, Laura Mercatali, Silvia Nicolini, Federica Pieri, Dino Amadori, Toni Ibrahim
INTRODUCTION: Pulmonary carcinoids (PCs) are classed according to the World Health Organization 2004 classification as typical or atypical carcinoids. Owing to their rarity, no dedicated clinical trials with somatostatin analogs (SSAs) have been carried out on primary PCs. PATIENTS AND METHODS: From January 2007 to December 2015, 30 patients with metastatic PCs underwent first-line SSA treatment (20 with octreotide long-acting repeatable 30 mg and 10 with lanreotide 120 mg every 28 days)...
November 21, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27933171/active-postoperative-acromegaly-sustained-remission-after-discontinuation-of-somatostatin-analogues
#8
Cristina Alvarez-Escola, Jersy Cardenas-Salas
: In patients with active acromegaly after pituitary surgery, somatostatin analogues are effective in controlling the disease and can even be curative in some cases. After treatment discontinuation, the likelihood of disease recurrence is high. However, a small subset of patients remains symptom-free after discontinuation, with normalized growth hormone (GH) and insulin-like growth factor (IGF1) levels. The characteristics of patients most likely to achieve sustained remission after treatment discontinuation are not well understood, although limited evidence suggests that sustained remission is more likely in patients with lower GH and IGF1 levels before treatment withdrawal, in those who respond well to low-dose treatment, in those without evidence of adenoma on an MRI scan and/or in patients who receive long-term treatment...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27913608/the-clinical-utility-of-circulating-neuroendocrine-gene-transcript-analysis-in-well-differentiated-paragangliomas-and-pheochromocytomas
#9
M Pęczkowska, J Cwikla, M Kidd, A Lewczuk, A Kolasinska-Ćwikła, D Niec, I Michałowska, A Prejbisz, A Januszewicz, J Chiarelli, L Bodei, I Modlin
CONTEXT: Paragangliomas and pheochromocytomas (PPGLs) exhibit variable malignancy, which is difficult to determine by histopathology, amine measurements or tissue genetic analyses. OBJECTIVE: To evaluate whether a 51-neuroendocrine gene blood analysis has clinical utility as a diagnostic and prognostic marker. DESIGN: Prospective cohort study. Well-differentiated PPGLs (n = 32), metastatic (n = 4); SDHx mutation (n = 25); 12 biochemically active, Lanreotide treated (n = 4)...
February 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27900635/somatostatin-and-dopamine-receptor-regulation-of-pituitary-somatotroph-adenomas
#10
REVIEW
Anat Ben-Shlomo, Ning-Ai Liu, Shlomo Melmed
Somatostatin and dopamine receptors are expressed in normal and tumoral somatotroph cells. Upon receptor stimulation, somatostatin and the somatostatin receptor ligands octreotide, lanreotide, and pasireotide, and to a lesser extent, dopamine and the dopamine analogs bromocriptine and cabergoline, suppress growth hormone (GH) secretion from a GH-secreting pituitary somatotroph adenoma. Somatostatin and dopamine receptors are Gαi-protein coupled that inhibit adenylate cyclase activity and cAMP production and reduce intracellular calcium concentration and calcium flux oscillations...
November 29, 2016: Pituitary
https://www.readbyqxmd.com/read/27874199/glucose-and-lipid-levels-with-lanreotide-autogel-120-mg-in-treatment-na%C3%A3-ve-patients-with-acromegaly-data-from-the-primarys-study
#11
Philippe J Caron, Stephan Petersenn, Aude Houchard, Caroline Sert, John S Bevan
OBJECTIVE: Impaired glycaemic control, characteristic of acromegaly, can be exacerbated by treatment with somatostatin analogues (SSAs), particularly those with multireceptor activity. We present data from the PRIMARYS study on the impact of the SSA lanreotide, associated with tumour volume and hormonal improvements, on glucose and other metabolic parameters in acromegaly. DESIGN: PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks...
November 22, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27857269/neuroendocrine-tumors-and-lanreotide-depot-clinical-considerations-and-nurse-and-patient-preferences
#12
Pamela Ryan, Alexandria T Phan, Daphne T Adelman, Michiko Iwasaki
BACKGROUND: Somatostatin analogs (SSAs) are a mainstay therapy for the treatment of carcinoid syndrome associated with neuroendocrine tumors (NETs). They are effective for a range of gastroenteropancreatic NETs (GEP-NETs). Lanreotide depot (Somatuline®) is an SSA that is approved for the treatment of GEP-NETs to improve progression-free survival (PFS). OBJECTIVES: The article reviews the efficacy, safety, and administration of lanreotide depot and relates those attributes to considerations and preferences of oncology nurses and their patients...
December 1, 2016: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/27822010/clinical-utility-of-lanreotide-autogel-%C3%A2-in-gastroenteropancreatic-neuroendocrine-tumors
#13
REVIEW
Rosa Maria Paragliola, Alessandro Prete, Giampaolo Papi, Francesco Torino, Andrea Corsello, Alfredo Pontecorvi, Salvatore Maria Corsello
Somatostatin analogs (SSAs), which were initially used to control hormonal syndromes associated with neuroendocrine neoplasms (NENs), have been successfully proposed as antiproliferative agents, able to control tumor growth in patients affected by gastroenteropancreatic (GEP)-NENs. The development of long-acting formulations of SSAs which require only weekly or monthly injections can improve patient compliance. In particular, lanreotide (LAN) Autogel(®), which is a viscous aqueous formulation supplied in ready-to-use prefilled syringes, can be administered every 28-56 days...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27778296/somatostatin-receptor-ligands-in-acromegaly-clinical-response-and-factors-predicting-resistance
#14
REVIEW
Rosa Maria Paragliola, Salvatore Maria Corsello, Roberto Salvatori
INTRODUCTION: Somatostatin (SST) receptor ligands (SRL), in particular those of first generation (Octreotide and Lanreotide), are widely used in medical treatment of acromegaly, but they assure biochemical control of disease (and the possibility of an improvement of clinical symptoms and tumor shrinkage), only in a subset of patients. DISCUSSION: The mechanisms underlying the so called "SRL resistance" are various and involve in particular SST receptor expression and molecular pathways of signal transduction...
October 24, 2016: Pituitary
https://www.readbyqxmd.com/read/27769969/management-of-neuroendocrine-tumors
#15
REVIEW
Clement Chung
PURPOSE: Current strategies for managing neuroendocrine tumors (NETs) in adult patients are reviewed, with a focus on medication safety concerns. SUMMARY: NETs usually originate in the gastrointestinal or bronchopulmonary tract. Symptoms due to hormonal hypersecretion often occur in patients with foregut or midgut NETs or liver metastases. Surgical resection is recommended for most localized NETs, while systemic cytotoxic chemotherapy is typically used for high-grade and pancreatic tumors...
November 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27721778/unresectable-recurrent-multiple-meningioma-a-case-report-with-radiological-response-to-somatostatin-analogues
#16
Ana Ortolá Buigues, Irene Crespo Hernández, Manuela Jorquera Moya, Jose Ángel Díaz Pérez
Medical treatment of meningiomas is reserved for cases in which surgery and radiotherapy have failed. Given that a high percentage of meningiomas express somatostatin receptors, treatment with somatostatin analogues has been proposed. In addition, these medications have been shown to have an antiproliferative and antiangiogenic effect in vitro. To date, very few cases with clinical response and none with radiological response have been described. The case described here is the first to report a radiological response...
May 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27697899/somatostatin-analogues-in-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-past-present-and-future
#17
REVIEW
Kjell Öberg, Steven W J Lamberts
Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1) levels. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) constitute a heterogeneous group of tumours that can secrete serotonin and a variety of peptide hormones that may cause characteristic symptoms known as carcinoid syndrome or other symptoms and hormonal hypersecretion syndromes depending on the tumour's site of origin...
December 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27697568/somatostatin-analogues-compared-with-placebo-and-other-pharmacologic-agents-in-the-management-of-symptoms-of-inoperable-malignant-bowel-obstruction-a-systematic-review
#18
REVIEW
George P Obita, Elaine G Boland, David C Currow, Miriam J Johnson, Jason W Boland
CONTEXT: Somatostatin analogues are commonly used to relieve symptoms in malignant bowel obstruction (MBO) but are more expensive than other antisecretory agents. OBJECTIVES: To evaluate the evidence of effectiveness of somatostatin analogues compared with placebo and/or other pharmacologic agents in relieving vomiting in patients with inoperable MBO. METHODS: MEDLINE, EMBASE, CINAHL, and The Cochrane Controlled Trials Register databases were systematically searched; reference lists of relevant articles were hand searched...
December 2016: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/27682353/clinical-outcomes-and-self-reported-symptoms-in-patients-with-acromegaly-eight-year-follow-up-of-a-lanreotide-study
#19
Shafaq Khairi, Babak Torabi Sagvand, Karen J Pulaski-Liebert, Nicholas A Tritos, Anne Klibanski, Lisa B Nachtigall
OBJECTIVES: The aim of this study was to evaluate the proportion of patients with acromegaly who remained on long-term lanreotide depot after completion of an open label multicenter phase III clinical trial (SALSA), compare symptom score at long-term follow-up with baseline and correlate these with individual longitudinal clinical outcomes. METHODS: Records of all subjects previously enrolled at the Massachusetts General Hospital site of SALSA were reviewed. Those who remained on lanreotide were interviewed and asked to complete a questionnaire that they had completed in SALSA in 2007 regarding their current symptomatology and injection side effects as well as to complete the Acromegaly Quality of life questionnaire...
September 28, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27635672/treatment-of-symptomatic-neuroendocrine-tumor-syndromes-recent-advances-and-controversies
#20
Tetsuhide Ito, Lingaku Lee, Robert T Jensen
INTRODUCTION: Neuroendocrine tumors(NETs), once thought rare, are increasing in frequency in most countries and receiving increasing-attention. NETs present two-treatment problems. A proportion is aggressive and a proportion has a functional, hormone-excess-state(F-NET) each of which, must be treated. Recently, there have been many advances, well-covered in reviews/consensus papers on imaging-NETs; new, novel anti-tumor treatments and understanding their pathogenesis. However, little attention has been paid to advances in the treatment of the hormone-excess-state...
September 16, 2016: Expert Opinion on Pharmacotherapy
keyword
keyword
81166
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"